SUNPHARMA

Sun Pharma continues to lead the Indian pharma industry with a strong US generics portfolio and growing specialty business. Its dermatology and ophthalmology segments are performing well, and India’s domestic formulations business remains resilient. The company has improved margins through cost optimization and product rationalization. With a focus on innovation, global expansion, and steady cash flows, Sun Pharma is positioned as a steady compounder in healthcare—offering both growth and defensive characteristics.